Cyclophosphamide, epirubicin, high-dose folinic acid and 5-fluorouracil (super-FEC) as first-line chemotherapy for advanced breast cancer: Preliminary results

  • Zaniboni A
  • Simoncini E
  • Marpicati P
 et al. 
  • 5


    Mendeley users who have this article in their library.
  • 9


    Citations of this article.


Forty patients with metastatic breast cancer were treated with a new combination regimen consisting of cyclophosphamide, epirubicin, high-dose folinic acid and 5-fluorouracil (super-FEC). A major objective response was observed in 32 patients (80%). Among these, 11 patients (27%) experienced a complete remission. The median duration of response was 10+ and 12+ months for CR and PR, respectively. The most common side-effect was oral mucositis (Grade III = nine patients; grade IV = two patients), while haematological toxicity was virtually absent. Considering the high-risk characteristics of the vast majority of the enrolled patients (75% had dominant visceral disease), these preliminary results suggest that super-FEC has a powerful activity in poor-prognosis metastatic breast cancer with an acceptable degree of toxicity. © 1989.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Alberto Zaniboni

  • Edda Simoncini

  • Patrizia Marpicati

  • Elisabetta Montini

  • Vittorio Ferrari

  • Amelio Ferragni

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free